• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vatalanib in advanced colorectal cancer: two studies with identical results.

作者信息

Sobrero Alberto F, Bruzzi Paolo

出版信息

J Clin Oncol. 2011 May 20;29(15):1938-40. doi: 10.1200/JCO.2010.33.2429. Epub 2011 Apr 4.

DOI:10.1200/JCO.2010.33.2429
PMID:21464409
Abstract
摘要

相似文献

1
Vatalanib in advanced colorectal cancer: two studies with identical results.凡他尼布治疗晚期结直肠癌：两项结果相同的研究。
J Clin Oncol. 2011 May 20;29(15):1938-40. doi: 10.1200/JCO.2010.33.2429. Epub 2011 Apr 4.
2
Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.靶向治疗实践：贝伐单抗和瓦他拉尼治疗晚期结直肠癌的Ⅲ期试验经验教训
Oncologist. 2007 Apr;12(4):443-50. doi: 10.1634/theoncologist.12-4-443.
3
Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer.目前关于PTK787的研究，一种用于治疗结直肠癌的血管内皮生长因子口服抑制剂。
Clin Colorectal Cancer. 2003 Nov;3(3):147-9. doi: 10.1016/S1533-0028(11)70081-0.
4
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.用于评估血管内皮生长因子（VEGF）受体抑制剂PTK787/ZK 222584（PTK/ZK）药理活性的生物标志物：小鼠黑色素瘤转移模型中的生物学活性向晚期结直肠癌肝转移患者I期研究的转化
Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. doi: 10.1007/s00280-005-0120-6. Epub 2005 Sep 20.
5
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.癌症患者中瓦他拉尼（PTK787/ZK-222584）的代谢与处置
Drug Metab Dispos. 2006 Nov;34(11):1817-28. doi: 10.1124/dmd.106.009944. Epub 2006 Aug 1.
6
PTK/ZK (Novartis).PTK/ZK（诺华公司）
IDrugs. 2003 Aug;6(8):787-94.
7
The fight against cancer: the next round.抗癌之战：新一轮较量。
Drug Discov Today. 2004 Nov 15;9(22):947-8. doi: 10.1016/S1359-6446(04)03282-9.
8
Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.瓦他拉尼：一种用于实体瘤的血管生成酪氨酸激酶抑制剂的临床开发
Expert Opin Investig Drugs. 2007 Mar;16(3):367-79. doi: 10.1517/13543784.16.3.367.
9
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.一项随机、安慰剂对照、III 期研究，评估一线奥沙利铂为基础的化疗联合 PTK787/ZK 222584（一种口服血管内皮生长因子受体抑制剂）治疗转移性结直肠腺癌患者的疗效。
J Clin Oncol. 2011 May 20;29(15):1997-2003. doi: 10.1200/JCO.2010.29.4496. Epub 2011 Apr 4.
10
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.乳酸脱氢酶 5 表达对接受 PTK787/ZK 222584（凡德他尼）抗血管生成治疗的结直肠癌患者的预后和预测作用。
Clin Cancer Res. 2011 Jul 15;17(14):4892-900. doi: 10.1158/1078-0432.CCR-10-2918. Epub 2011 Jun 1.

引用本文的文献

1
Single-cell RNA-seq analysis of cancer-endothelial cell interactions in primary tumor and peritoneal metastasis from a single patient with colorectal cancer.对一名结直肠癌患者的原发性肿瘤和腹膜转移灶中癌-内皮细胞相互作用进行单细胞RNA测序分析。
BJC Rep. 2024 Nov 18;2(1):88. doi: 10.1038/s44276-024-00112-3.
2
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.一项评估血管内皮生长因子受体（VEGFR）激酶抑制剂凡德他尼与 mTOR 抑制剂依维莫司联合用于治疗晚期实体瘤患者的 I 期临床研究。
Invest New Drugs. 2020 Dec;38(6):1755-1762. doi: 10.1007/s10637-020-00936-z. Epub 2020 Apr 24.
3
Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer.
旨在阐明瑞戈非尼在难治性转移性结直肠癌治疗中的作用。
ESMO Open. 2017 Jul 29;2(3):e000205. doi: 10.1136/esmoopen-2017-000205. eCollection 2017.
4
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.癌症抗血管生成治疗的当前挑战与纳米治疗的前景。
Theranostics. 2018 Jan 1;8(2):533-548. doi: 10.7150/thno.21674. eCollection 2018.
5
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?结直肠癌抗血管生成治疗反应的标志物：我们目前的状况及下一步该怎么做？
Clin Med Insights Oncol. 2016 Apr 27;10(Suppl 1):41-55. doi: 10.4137/CMO.S34542. eCollection 2016.
6
Novel Therapies in Development for Metastatic Colorectal Cancer.转移性结直肠癌的新型治疗方法研发
Gastrointest Cancer Res. 2014 Sep;7(4 Suppl 1):S2-7.
7
Recent developments in receptor tyrosine kinases targeted anticancer therapy.受体酪氨酸激酶靶向抗癌治疗的最新进展。
Vet World. 2016 Jan;9(1):80-90. doi: 10.14202/vetworld.2016.80-90. Epub 2016 Jan 29.
8
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.在一项针对晚期实体瘤患者的I期研究中，PF-00337210的药效学指导剂量选择。
Cancer Chemother Pharmacol. 2016 Mar;77(3):527-38. doi: 10.1007/s00280-016-2958-1. Epub 2016 Jan 20.
9
Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.肾癌细胞中FLT1的表观遗传沉默导致靶向血管内皮生长因子途径的药物疗效降低。
Clin Epigenetics. 2015 Sep 16;7:99. doi: 10.1186/s13148-015-0134-9. eCollection 2015.
10
A synthetic dl-nordihydroguaiaretic acid (Nordy), inhibits angiogenesis, invasion and proliferation of glioma stem cells within a zebrafish xenotransplantation model.一种合成的 dl-正去氢愈创木酸（Nordy），在斑马鱼异种移植模型中抑制神经胶质瘤干细胞的血管生成、侵袭和增殖。
PLoS One. 2014 Jan 15;9(1):e85759. doi: 10.1371/journal.pone.0085759. eCollection 2014.